Artiva Biotherapeutics, Inc. Common Stock
$8.44
-$0.16 (-1.86%)
$8.35Day Range$8.72
Key Statistics
Market Cap
$412.63M
Shares Outstanding
48.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 19, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$8.66
Day High
$8.72
Day Low
$8.35
Volume
456.5K
VWAP
$8.48
Prev Close
$8.60
Transactions
--
Acc. Volume
--
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836115 employees5505 MOREHOUSE DRIVE, SAN DIEGO, CA, 92121(858) 267-4467IPO Jul 19, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001817241
- Composite FIGI
- BBG00VPZJ0F9
- Share Class FIGI
- BBG00VPZJ0G8
- Ticker Root
- ARTV
- SIC Code
- 2836
About Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock
Artiva Biotherapeutics, Inc. Common Stock (ARTV) closed the 2026-09-17 session at $8.44, down 1.86% versus the previous close (-0.16). The stock opened at $8.66 and traded between $8.35 and $8.72 during that session. Session trading volume was 457K shares. The volume-weighted average price (VWAP) is $8.48.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Artiva Biotherapeutics, Inc. Common Stock has a market capitalization of $412.6 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ARTV is listed on the XNAS exchange. The company employs approximately 115 people. Artiva Biotherapeutics, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2024-07-19.
On this page you can find market ARTV stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.